Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Dalton Pharma Services
Dalton Pharma Services
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Tetra Bio-Pharma engages Dalton Pharma for GMP manufacturing
Tetra Bio-Pharma has awarded the contract for the manufacturing of its active pharmaceutical ingredient ARDS-003
Manufacturing
Dalton expands sterile fill/finish capabilities
The Toronto-based pharma services company said investment is part of a US$10m facility and capital expansion
Manufacturing
Dalton Pharma Services completes $5 million expansion
The project was supported by CA$2.085 million of funding from FedDev Ontario
Manufacturing
Lonza and Dalton to provide integrated chemistry services
Dalton adds geographic diversification to Lonza facilities network
Dalton's GMP oligonucleotide facility ready to roll
<p>Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.</p>
Subscribe now